

Godasi S R S N K Naidu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7049955/publications.pdf>

Version: 2024-02-01

41
papers

371
citations

759233

12
h-index

839539

18
g-index

41
all docs

41
docs citations

41
times ranked

569
citing authors

#	ARTICLE	IF	CITATIONS
1	Life-threatening corrosive injury with hepato-renal-pulmonary failure in boric acid poisoning. Postgraduate Medical Journal, 2022, 98, 70-71.	1.8	1
2	<scp>VEXAS</scp> syndrome with systemic lupus erythematosus: expanding the spectrum of associated conditions. Arthritis and Rheumatology, 2022, 74, 369-371.	5.6	16
3	Clinical presentation and treatment outcomes of arterial involvement in Behçet's disease: a single-centre experience. Rheumatology International, 2022, 42, 115-120.	3.0	2
4	ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review. Rheumatology International, 2022, 42, 749-758.	3.0	45
5	Increased gene expression of B cell-activating factor of tumor necrosis factor family, in remitting antineutrophil cytoplasmic antibody-associated vasculitis patients. International Journal of Rheumatic Diseases, 2022, 25, 218-227.	1.9	4
6	Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis—a real-life experience. Clinical Rheumatology, 2021, 40, 645-651.	2.2	15
7	Efficacy of a step-down regimen of oral prednisolone in axial spondyloarthritis: result of a double-blind randomized controlled trial (COBRA-AS Study). Rheumatology, 2021, 60, 1932-1941.	1.9	8
8	Looking at the lobule-importance of ears and years in rheumatology. Rheumatology, 2021, 60, 477-478.	1.9	0
9	Deficiency of Adenosine Deaminase 2 in Adults and Children: Experience From India. Arthritis and Rheumatology, 2021, 73, 276-285.	5.6	43
10	Validation of the provisional seven-item criteria for the diagnosis of polyarteritis nodosa. Rheumatology International, 2021, 41, 1651-1655.	3.0	3
11	Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: Are the Visual Outcomes Different From Giant Cell Arteritis? Comment on the Article by Delaval et al. Arthritis and Rheumatology, 2021, 73, 1345-1346.	5.6	1
12	Comparison of two dose escalation strategies of methotrexate in active rheumatoid arthritis: a multicentre, parallel group, randomised controlled trial. Annals of the Rheumatic Diseases, 2021, 80, 1376-1384.	0.9	5
13	Assessing methotrexate intolerance and its prevalence in rheumatoid arthritis: Development and validation of the MISA questionnaire. International Journal of Rheumatic Diseases, 2021, 24, 1294-1301.	1.9	4
14	Managing ANCA-associated vasculitis during the COVID-19 pandemic: results from an online survey. Rheumatology International, 2021, 41, 1941-1947.	3.0	3
15	Comment on: Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion. Rheumatology, 2021, 60, e113-e114.	1.9	0
16	Association of immunological features with clinical manifestations in primary Sjogren's syndrome: a single-center cross-sectional study. Clinical and Experimental Medicine, 2021, , 1.	3.6	2
17	Fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis, assessment of disease activity and therapeutic response in relapsing polychondritis. Rheumatology, 2020, 59, 99-106.	1.9	16
18	Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial. Rheumatology International, 2020, 40, 207-216.	3.0	26

#	ARTICLE	IF	CITATIONS
19	Response to: Biosimilars for vasculitis: promise requires validation by quality studies. <i>Clinical Rheumatology</i> , 2020, 39, 3155-3156.	2.2	0
20	Acute myocardial dysfunction in lupus: outcomes in Asian Indians. <i>Clinical Rheumatology</i> , 2020, 39, 3661-3667.	2.2	1
21	Intravenous Immunoglobulin for the Rescue in Refractory Cutaneous Lupus. <i>Indian Dermatology Online Journal</i> , 2020, 11, 1003-1004.	0.5	0
22	Novel <i>CECR1</i> gene mutations causing deficiency of adenosine deaminase 2, mimicking antiphospholipid syndrome. <i>Rheumatology</i> , 2019, 58, 181-182.	1.9	10
23	FRI0649...PREVALENCE OF ANCA AND ANA IN PATIENTS WITH PULMONARY TUBERCULOSIS. , 2019, , .		0
24	FRI0280...BAFF AND APRIL GENE EXPRESSION IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS. , 2019, , .		0
25	AB0615...PREVALENCE OF DEPRESSION, ANXIETY, FATIGUE AND SLEEP DISTURBANCES IN PATIENTS OF RA, SLE AND GPA. , 2019, , .		0
26	SAT0244...EXPANDING SPECTRUM OF ADENOSINE DEAMINASE 2 (DADA2) MANIFESTATIONS: EXPERIENCE 13 PATIENTS FROM INDIA. , 2019, , .		0
27	Vasculitis research: Current trends and future perspectives. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 10-20.	1.9	10
28	Is granulomatosis with polyangiitis in Asia different from the West?. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 90-94.	1.9	21
29	“MAINRITSAN2-the future”™, with some doubts!. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e139-e139.	0.9	2
30	Is rituximab “The Wonder Drug” for antineutrophil cytoplasmic antibodies-associated vasculitis?. <i>Indian Journal of Rheumatology</i> , 2019, 14, 4.	0.4	1
31	Reniform abdominal halo in diabetes mellitus. <i>Postgraduate Medical Journal</i> , 2019, 95, 464-464.	1.8	0
32	OUP accepted manuscript. <i>Rheumatology</i> , 2019, 58, 737-738.	1.9	0
33	Clinical features and long-term outcomes of 105 granulomatosis with polyangiitis patients: A single center experience from north India. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 278-284.	1.9	29
34	A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 308-314.	1.9	28
35	Pulmonary Renal Syndrome. <i>Journal of the Association of Physicians of India</i> , The, 2018, 66, 11-13.	0.0	1
36	Current and Future Treatment Options for Takayasu Arteritis and Persistent Therapeutic Challenges. <i>Current Treatment Options in Rheumatology</i> , 2017, 3, 141-152.	1.4	0

#	ARTICLE	IF	CITATIONS
37	The role of danger-associated molecular patterns (DAMPs) in trauma and infections. Journal of Thoracic Disease, 2016, 8, 1406-1409.	1.4	30
38	Pauci-immune glomerulonephritis: does negativity of anti-neutrophilic cytoplasmic antibodies matters?. International Journal of Rheumatic Diseases, 2016, 19, 74-81.	1.9	14
39	Histopathological classification of pauci-immune glomerulonephritis and its impact on outcome. Rheumatology International, 2014, 34, 1721-1727.	3.0	27
40	Peripheral nervous system involvement in Sjogren's syndrome and its impact on quality of life. Clinical and Experimental Medicine, 0, , .	3.6	3
41	Calcinosis cutis with amyopathic dermatomyositis. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.5	0